Can pharmacies prescribe weight-loss injections on the NHS?

Who can get tirzepatide on the NHS today?

A narrower group than the licence, and a narrower group again than NICE. The MHRA licence for weight management covers adults with a BMI of 30 or more, or 27 or more with a weight-related condition. NICE's appraisal, TA1026, recommends tirzepatide for adults with a BMI of at least 35 and at least one weight-related medical condition. Thresholds are usually reduced by 2.5 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. Treatment goes with a reduced-calorie diet and increased physical activity.

Then NHS England phases even that. NICE agreed a funding variation that lets the NHS bring the eligible population in over a maximum of 12 years. NHS England's interim commissioning guidance, first published in March 2025 and updated on 2 April 2026, sets the order. Five conditions count as qualifying comorbidities: atherosclerotic cardiovascular disease, hypertension, dyslipidaemia, obstructive sleep apnoea and type 2 diabetes. The cohorts are below.

The guidance puts the first three years' cohort at 220,000 people, out of an eligible population of about 3.4 million. Semaglutide (Wegovy) is tighter still. NICE's TA875 restricts it to specialist multidisciplinary weight management services, for a maximum of two years. Treatment may stop if less than 5 per cent of starting weight is lost after six months. Tirzepatide has the same 5 per cent reassessment point at six months but, in NHS England's words, "does not have a set 'stopping rule' or maximum treatment period".

Who prescribes it, and where do pharmacies fit?

GP practices and specialist weight management services prescribe. Pharmacies dispense. NHS England's guidance says tirzepatide "is recommended by NICE for use in primary care settings and specialist weight management services", and it builds the primary care side into the GP contract. The QOF 2026/27 update introduces two obesity indicators, one of which, OB005, "supports the consideration of weight-management pharmacotherapies as per the NICE Guidance on obesity management". Primary care management costs sit inside QOF. Behavioural wraparound care is funded separately and held centrally by NHS England.

Community pharmacy appears in the guidance in one place only, and it is not as a prescriber. Where an integrated care board uses an online prescribing pathway, commissioners "must ensure compliance with the General Pharmaceutical Council (GPhC) guidance on safe prescribing practices by all contracted service providers". Prescribing decisions "cannot be based solely on the information provided in an online questionnaire". That is the GPhC's February 2025 distance-selling standard imported into NHS commissioning, and it means an NHS online pathway must meet the same verification rules as a private one. Those rules are set out in our guide to the verification duties.

Could a pharmacist prescriber be one of those contracted providers? Nothing in the guidance forbids it, and The Pharmaceutical Journal reported on 2 July 2026 that some pharmacies had explored pharmacist prescribing for weight management under NHS England's pathfinder programme. But that is local contracting, not a service a pharmacy can sign up to. The national position in July 2026 is that pharmacies dispense NHS tirzepatide prescriptions written elsewhere.

Is weight management in the 2026/27 pharmacy contract?

No. The Community Pharmacy Contractual Framework for 2026/27, announced on 29 May 2026, does not mention weight management, obesity or GLP-1 medicines. It funds a new NHS independent prescribing service from autumn 2026, with a £500 set-up payment and a £525 monthly infrastructure payment. Prescribing sits within Pharmacy First, the contraception service and supply-chain alternatives, plus up to five prescribing-only Pharmacy First pathways subject to clinical assessment. None of them is weight management.

The gap is not an oversight. The NHS pathway requires mandatory wraparound support with nutritional and dietetic advice as a minimum, plus behavioural change components, and NHS England is procuring that nationally. A pharmacy service without the wraparound would not meet the commissioning guidance, and a pharmacy service with it would need funding the settlement did not contain. What the new prescribing service does cover, and whether it pays, is analysed in our guide to independent prescribing in Pharmacy First.

Why is NHS access so slow?

Because the rollout was designed to be slow, and delivery is running behind even that. The design is the funding variation: 220,000 people in three years against 3.4 million eligible is about 6 per cent of the eligible population by 2028. On 3 June 2026 the Health and Social Care Committee told NHS England and the health department that just 1 per cent of eligible patients were accessing NHS weight-loss services. That is according to The Pharmaceutical Journal's report of the session.

The constraint is care, not stock. Every NHS patient must receive wraparound support, and NHS England went to market for a national behavioural support provider in May 2025 before the primary care start date of 23 June 2025. Practices identify and invite eligible patients; four of five London integrated care boards had commissioned specialist services suitable for the newer medicines by autumn 2025, according to evidence to the London Assembly. Meanwhile NHS dispensing data shows how much of the volume is diabetes rather than obesity. More than 4 million items of tirzepatide and semaglutide were dispensed in England in 2025/26, according to the NHS Business Services Authority's Prescription Cost Analysis of 4 June 2026. The PJ reported the figure. The obesity cohort is a fraction of that.

What do the June 2026 pilots change?

They put community pharmacy inside an NHS obesity pathway for the first time, on a test basis. On 27 June 2026 the government announced the Obesity Pathway Innovation Programme. It combines up to £50 million from the Department for Science, Innovation and Technology with up to £35 million from Eli Lilly, £85 million in all. It funds 12 projects across the UK, due to run until March 2029. Two involve pharmacies directly. Leicester, Leicestershire and Rutland will open six neighbourhood hubs in community pharmacies and gyms. South London will run a pharmacy-based service with exercise groups. The projects offer "lifestyle wraparound services, such as nutritionists, psychologists, social prescribing, and, where clinically appropriate, pharmaceutical obesity treatments".

The policy line behind it is a year old. Launching the 10 Year Health Plan on 3 July 2025, the Prime Minister promised "innovative weight loss services, available in pharmacies". The plan committed to testing delivery models including online-only, high-street and rural options. The National Pharmacy Association called the June 2026 announcement "the announcement community pharmacy has been waiting for". The Company Chemists' Association said the pilots would "provide valuable evidence". Evidence is the right word. A pilot that runs to 2029 is an argument for a service in the 2029/30 contract, not a service now.

Where does private pharmacy prescribing fit?

It is where almost everyone on these medicines actually is. The Company Chemists' Association told the London Assembly in September 2025 that 95 per cent of people using GLP-1 medicines access them privately. IQVIA data reported by The Pharmaceutical Journal put UK purchases at 1.6 million packs of Wegovy and Mounjaro in April 2025, more than 1.4 million of them through pharmacies. The PJ's July 2026 feature cites 2.5 million people a month accessing GLP-1 medicines privately by the end of 2025. Against 220,000 NHS places over three years, private supply is the market and NHS supply is the exception.

That market runs on pharmacist independent prescribers and contracted prescribing platforms, under the GPhC's February 2025 distance-services guidance and its April 2025 prescriber guidance. The licence sets the floor: a BMI of 30, or 27 with a weight-related condition. The GPhC sets the process: identity confirmed, weight and BMI independently verified, a two-way consultation, the GP told, and monitoring in place before prescribing. The commercial pressure is real. The GPhC's April 2026 review found that the Mounjaro list price increase announced in August 2025 generated 78 per cent of all pricing-related concerns within two months. How the private model holds up, and what a durable service looks like, is covered in our analysis of the weight management boom.

The private channel is also where new products land first. The MHRA approved the oral form of Wegovy on 11 June 2026, in 1.5 mg, 4 mg, 9 mg and 25 mg strengths, for the same licensed population. It is not available on the NHS, and a NICE evaluation will follow. Until then it is a private, prescription-only product, and advertising it to the public is as unlawful as advertising the injections.

Can patients move between NHS and private?

From NHS to private, yes; from private to NHS, only by qualifying. Nothing in NHS England's guidance prevents an NHS-eligible patient from paying privately instead, and with 220,000 places against millions of eligible people, many do. The private prescriber then owes the full GPhC process, including sharing the prescription with the GP with the patient's consent, or recording why not. That sharing matters clinically: the MHRA's pancreatitis update of 29 January 2026 tells clinicians to ask about privately prescribed GLP-1 use because it "may not appear on the patient's medical history".

In the other direction there is no fast lane. NHS England's guidance does not address patients already taking privately obtained tirzepatide, so a private patient enters the NHS pathway only when their BMI and comorbidities place them in the current cohort. A private history is not an NHS entitlement. Where a patient does transfer, the NHS prescriber will want the private record: verified baseline, dose history, side effects and reviews. A pharmacy whose records can supply that is doing the patient a service and demonstrating the standard the GPhC now inspects against, as our guide to weight-loss monitoring requirements explains.

Key takeaways

FAQs